Tokai University Hospital- Isehara Campus

Isehara 259-1193

1 studies enrolling now · 3 studies all time

What they study most

Chronic Lymphocytic Leukemia, HER2-Positive Primary Breast Cancer, Non-Hodgkin Lymphoma, Residual Invasive Breast Cancer

Studies at this site

• A Master Protocol to Evaluate the Long-Term Safety of (LY3527727) Pirtobrutinib — Recruiting now
• A Study of (LY3527727) Pirtobrutinib in Participants With Previously Treated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma or Non-Hodgkin Lymphoma — Recruiting now
• A Study of Trastuzumab Deruxtecan (T-DXd) Versus Trastuzumab Emtansine (T-DM1) in High-risk HER2-positive Participants With Residual Invasive Breast Cancer Following Neoadjuvant Therapy (DESTINY-Breast05) — Running, not enrolling